May 2010
Worldwide Biotech;May2010, Vol. 22 Issue 5, p3
Trade Publication
The article reports on the exclusive rights granted by Pro-Pharmaceuticals Inc. to PROCAPS SA to market and sell Davanat for the treatment of cancer in Colombia. It mentions that Pro-Pharmaceuticals develops therapeutics targeting Galectin receptors to treat cancer and fibrosis while PROCAPS is a privately held pharmaceutical firm. As part of the agreement, PROCAPS will be responsible for obtaining regulatory and pricing approval as well as vial filling, packaging, marketing and distribution.


Related Articles

  • Pro-Pharma Sees Clear Path to NDA for Davanat in Cancer. Hollingsworth, Catherine // BioWorld Today;1/30/2009, Vol. 20 Issue 19, p1 

    The article reports the possibility that Pro-Pharmaceuticals Inc. will be able to obtain U.S. approval of its add-on cancer therapy Davanat by providing a pharmacokinetic analysis of about 60 patients. The approval will enable the use of Davanat to treat colorectal cancer. David Platt of...

  • Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Glaspy, J.A.; Jadeja, J.S.; Justice, G.; Kessler, J.; Richards, D.; Schwartzberg, L.; Tchekmedyian, N.S.; Armstrong, S.; O'Byrne, J.; Rossi, G.; Colowick, A.B. // British Journal of Cancer;7/29/2002, Vol. 87 Issue 3, p268 

    Assesses the safety of darbepoetin alfa in patients receiving cancer chemotherapy. Feasibility of administering darbopoetin every versus every two weeks; Drug dosage; Dose-response relationships.

  • Preface [Hot topic: Anti-Cancer Drugs (Executive Editor : Elke Bergmann-Leitner)]. Bergmann-Leitner, Elke // Current Pharmaceutical Design;Oct2003, Vol. 9 Issue 25, p1 

    Despite decades of intensive research there have only been a limited number of small success stories in the area of cancer treatment. This issue of Current Pharmaceutical Design features several novel approaches in the development of anti-cancer treatments. Cancer, being one of the leading...

  • Combinations of Targeted Therapies Take Aim at Multiple Pathways. Goldman, Bruce // JNCI: Journal of the National Cancer Institute;11/19/2003, Vol. 95 Issue 22, p1656 

    Part I. Focuses on the use of novel targeted drugs in the treatment of cancer. Differences of the drugs with existing products; Targeted drugs from various companies; Mechanism of action; Combination trials of targeted therapies.

  • Demand Grows for Early Access to Promising Cancer Drugs. Baldwin, Joyce // JNCI: Journal of the National Cancer Institute;11/20/2002, Vol. 94 Issue 22, p1668 

    Discusses the influence of expanded access programs in cancer patients' access to investigational drugs in the U.S. Patients' receipt of investigational drugs earlier than phase III of the clinical trial process; Patient advocacy groups' role in the growth of expanded access programs; Factors...

  • CME Questions.  // Clinical Oncology Alert;May2007, Vol. 23 Issue 5, p39 

    A quiz concerning the drugs for the treatment of cancer is presented.

  • Vandetanib Tablets (Zactima). Elliott, William T.; Chan, James // Internal Medicine Alert;5/15/2011, Vol. 33 Issue 9, p69 

    The article offers information on the effectiveness of Vandetanib tablets, marketed under the brand name Zactima from the company AstraZeneca, in treating patients with medullary thyroid cancer (MTC).

  • CME Question.  // Clinical Oncology Alert;Dec2009, Vol. 25 Issue 12, p96 

    A quiz related to cancer treatment and anticancer drugs is presented.

  • Targeted therapy pans out for treating cancer. McCann, Jean // Drug Topics;7/21/2003, Vol. 147 Issue 14, DRUG TOPICS FOR THE... p17 

    Focuses on clinical studies of targeted therapy for cancer, presented at the 39th annual meeting of the American Society of Clinical Oncology. Effectiveness of antiangiogenesis drugs in extending survival of patients with advanced cancer; Combination treatment for cancer; Phase III studies of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics